HTGM
NASDAQHTG Molecular Diagnostics Inc.
Website
News25/Ratings1
Latest news
25 items- NEWS12 Health Care Stocks Moving In Monday's Intraday SessionGainers Jin Medical International (NASDAQ:ZJYL) stock rose 58.4% to $13.51 during Monday's regular session. The current volume of 4.2 million shares is 8924.5% of Jin Medical International's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $104.7 million. Chinook Therapeutics (NASDAQ:KDNY) stock rose 58.31% to $37.98. Trading volume for this security as of 13:30 EST is 17.3 million, which is 2476.2% of its average full-day volume over the last 100 days. The company's market cap stands at $2.5 billion. Aesthetic Medical Intl (NASDAQ:AIH) stock rose 22.91% to $1.18. Trading volume for Aesthetic Medical Intl's stock is 542.6K as o
- NEWSWhy Asset Entities Shares Are Trading Higher By 142%? Here Are Other Stocks Moving In Monday's Mid-Day SessionGainers Asset Entities Inc. (NASDAQ:ASST) shares jumped 142% to $2.79 after the company announced the development of an AI bot as part of its AE360DDM suite of services on Discord. Micromobility.com Inc. (NASDAQ:MCOM) shares rose 91.2% to $0.44. Chinook Therapeutics, Inc. (NASDAQ:KDNY) jumped 55.9% to $37.40 after Novartis agreed to acquire the company for $40 per share in cash. Advanced Health Intelligence Ltd. (NASDAQ:AHI) shares gained 44% to $3.14 after jumping 581% on Friday. Auddia Inc. (NASDAQ:AUUD) shares climbed 39.4% to $0.6042. Auddia reported the launch of its faidr 3.0 mobile app. Infobird Co., Ltd (NASDAQ:IFBD) shares climbed 38.8% to $2.02. Infobird recently regaine
- INSIDERSEC Form 4 filed by Barat Stephen4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
- SECHTG Molecular Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
- NEWS12 Health Care Stocks Moving In Wednesday's Intraday SessionGainers Avalo Therapeutics (NASDAQ:AVTX) shares rose 17.3% to $3.53 during Wednesday's regular session. The company's market cap stands at $46.5 million. Journey Medical (NASDAQ:DERM) shares rose 15.59% to $1.84. Trading volume for this security as of 13:30 EST is 55.9K, which is 228.4% of its average full-day volume over the last 100 days. The company's market cap stands at $33.3 million. Societal CDMO (NASDAQ:SCTL) shares rose 15.14% to $0.9. Trading volume for Societal CDMO's stock is 81.4K as of 13:30 EST. This is 43.5% of its average full-day volume over the last 100 days. The company's market cap stands at $76.2 million. Microbot Medical (NASDAQ:MBOT) stock moved upwards by 14.79%
- NEWSStocks That Hit 52-Week Lows On WednesdayOn Wednesday, 29 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was NovoCure (NASDAQ:NVCR). The company with the smallest market cap to set a new 52-week low was HTG Molecular Diagnostics (NASDAQ:HTGM). PolarityTE (NASDAQ:PTE)'s stock traded down the lowest, falling 42.87% to reach a new 52-week low. Owlet (NYSE:OWLT) shares rebounded the highest, with shares trading up 0.1%, bouncing back after reaching its new 52-week low. Here is a list of stocks that set new 52-week lows on Wednesday: NovoCure (NASDAQ:NVCR) shares were down 1.26% for the day, having made a 52-week low of
- NEWSStocks That Hit 52-Week Lows On TuesdayOn Tuesday, 69 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Estee Lauder Cos (NYSE:EL) was the largest company by market cap to set a new 52-week low. The smallest company by market cap to hit a new 52-week low was Biodexa Pharmaceuticals (NASDAQ:BDRX). Westport Fuel Systems (NASDAQ:WPRT) shares dropped the most, trading down 848.41% to reach its new 52-week low. Greenidge Generation Hldg (NASDAQ:GREE) shares rebounded the highest, with shares trading up 0.0%, bouncing back after reaching its new 52-week low. The following stocks created new 52-week lows on Tuesday: Estee Lauder Cos (NYSE:EL) shares set a new 52-week low of $178.78. The stock trade
- NEWSWhy Are HTG Molecular Diagnostics Shares Plunging TodayHTG Molecular Diagnostics (NASDAQ:HTGM) stock is down on Tuesday after the company announced a Chapter 11 bankruptcy filing. According to the filing, HTG Molecular Diagnostics will operate as a "debtor-in-possession" business during the bankruptcy. It's also seeking a variety of first-day motions that will allow it to continue normal operations. The filing also accelerates the obligations of the company's debts, including a $2.68 million loan held by Silicon Valley Bank, now a division of First-Citizens Bank and Trust Company. HTG Molecular Diagnostics notified the termination of Senior Vice President and Chief Commercial Officer Byron Lawson at the start of the month. However, the
- NEWS12 Health Care Stocks Moving In Tuesday's Intraday SessionGainers Hoth Therapeutics (NASDAQ:HOTH) shares moved upwards by 66.5% to $3.13 during Tuesday's regular session. Trading volume for this security as of 13:30 EST is 88.5 million, which is 38144.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $10.3 million. Synlogic (NASDAQ:SYBX) stock rose 25.39% to $0.61. As of 13:30 EST, Synlogic's stock is trading at a volume of 413.1K, which is 135.4% of its average full-day volume over the last 100 days. The company's market cap stands at $41.6 million. Castle Biosciences (NASDAQ:CSTL) shares moved upwards by 23.62% to $14.41. Castle Biosciences's stock is trading at a volume of 3.1 million
- NEWSWhy THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionGainers Recruiter.com Group, Inc. (NASDAQ:RCRT) shares jumped 114% to $0.41. Recruiter.com signed a definitive agreement for planned purchase of fintech assets of GoLogiq. Hoth Therapeutics, Inc. (NASDAQ:HOTH) rose 96% to $3.6850 after the company announced preclinical results for HT-ALZ for the treatment of Alzheimer's disease. Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) shares rose 37.8% to $0.5928. Zura Bio Limited (NASDAQ:ZURA) shares gained 25% to $8.11 after the company completed approximately $80 million financing with the focus on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist. Xunlei Limited (NASDAQ:XNET) rose 22%
- NEWS12 Health Care Stocks Moving In Tuesday's Pre-Market SessionGainers Hoth Therapeutics (NASDAQ:HOTH) shares rose 99.5% to $3.75 during Tuesday's pre-market session. The company's market cap stands at $12.3 million. Novo Integrated Sciences (NASDAQ:NVOS) stock increased by 22.15% to $0.15. The market value of their outstanding shares is at $22.3 million. T2 Biosystems (NASDAQ:TTOO) stock increased by 18.14% to $0.08. The market value of their outstanding shares is at $2.0 million. Medigus (NASDAQ:MDGS) stock rose 16.61% to $5.14. The company's market cap stands at $8.4 million. Zura Bio (NASDAQ:ZURA) shares rose 15.55% to $7.5. The company's market cap stands at $238.5 million. PDS Biotechnology (NASDAQ:PDSB) shares increased by 13.16% to $7.39.
- NEWSWhy Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving PremarketGainers Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) shares rose 85.8% to $0.7985 in pre-market trading. Chijet Motor Company, Inc. (NASDAQ:TTOO) shares surged 51.3% to $0.1060 in pre-market trading after dipping around 31% on Monday. T2 Biosystems reported submission for the FDA breakthrough device designation for candida auris diagnostic test. Secoo Holding Limited (NASDAQ:SECO) gained 35.8% to $1.100 in pre-market trading. Zura Bio Limited (NASDAQ:ZURA) shares gained 35.4% to $8.79 in pre-market trading after the company completed approximately $80 million financing with the focus on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual ant
- SECHTG Molecular Diagnostics Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
- NEWS12 Health Care Stocks Moving In Monday's Intraday SessionGainers INVO Bioscience (NASDAQ:INVO) stock rose 50.9% to $0.32 during Monday's regular session. Trading volume for this security as of 13:30 EST is 5.4 million, which is 2816.2% of its average full-day volume over the last 100 days. The company's market cap stands at $4.4 million. Timber Pharmaceuticals (AMEX:TMBR) stock increased by 38.92% to $2.07. As of 13:30 EST, Timber Pharmaceuticals's stock is trading at a volume of 12.3 million, which is 18950.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.3 million. Pasithea Therapeutics (NASDAQ:KTTA) shares moved upwards by 24.99% to $0.5. Trading volume for Pasithea Therapeutics'
- NEWSStocks That Hit 52-Week Lows On TuesdayDuring Tuesday's morning session, 137 companies made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Bristol-Myers Squibb (NYSE:BMY) was the biggest company in terms of market cap to set a new 52-week low. NovaBay Pharmaceuticals (AMEX:NBY) was the smallest, in terms of market cap, to set a new 52-week low. Smart for Life (NASDAQ:SMFL)'s stock moved significantly downwards, trading down 37.8% to reach a new 52-week low. Nemaura Medical (NASDAQ:NMRD)'s stock showed potential to rebound, rebounding up 0.0% after reaching a new 52-week low. During the first half-hour of trading on Tuesday, the following stocks set new 52-week lows: Bristol-Myers Squibb (NYSE:BM
- NEWSHTG Molecular Diagnostics Said On May 18, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
- SECHTG Molecular Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
- PRHTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International ConventionTUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treat
- NEWSWhy Sunrise New Energy Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving PremarketGainers WeTrade Group, Inc. (NASDAQ:WETG) shares surged 93.7% to $0.0736 in pre-market trading after dropping around 15% on Tuesday. WeTrade Group recently received a notice of noncompliance from Nasdaq because it failed to timely file its 2022 annual report on form 10-K with the SEC. Smart for Life, Inc. (NASDAQ:SMFL) shares rose 47.4% to $3.42 in pre-market trading. Smart For Life recently announced a $900,000 registered direct offering priced at-the-market under Nasdaq rules. JE Cleantech Holdings Limited (NASDAQ:JCSE) shares gained 37.4% to $0.7163 in pre-market trading after dropping 13% on Tuesday. Sunrise New Energy Co., Ltd. (NASDAQ:EPOW) shares gained 35.2% to $2.61 in pre-m
- SECHTG Molecular Diagnostics Inc. filed SEC Form 8-K: Other Events8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
- NEWSHTG Highlights Rhe Advantages Of Its Drug Discovery EngineHTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostically across therapy areas. At the center of this approach is HTG's proprietary RNA profiling technologies, functionally married with an advanced medicinal chemistry using a novel artifici
- PRHTG Highlights the Advantages of Its Drug Discovery EngineTUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostically across therapy areas. At the center of this approach is HTG's proprietary RNA profiling technologies, functionally married with an adva
- PRHTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business HighlightsTUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG's proprietary RNA profiling technologies, functionally married with advanced medicinal chemistry using a novel artificial intelligence ("AI")-driven platform. This unique drug can
- NEWSHTG Molecular Diagnostics Q1 EPS $(2.28) Misses $(1.94) Estimate, Sales $1.03M Miss $1.60M EstimateHTG Molecular Diagnostics (NASDAQ:HTGM) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(1.94) by 17.53 percent. This is a 76.54 percent increase over losses of $(9.72) per share from the same period last year. The company reported quarterly sales of $1.03 million which missed the analyst consensus estimate of $1.60 million by 35.50 percent. This is a 12.84 percent decrease over sales of $1.18 million the same period last year.
- SECHTG Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)